Daiichi Sankyo: April-June Nexium Sales 6% of Full-Year Target, Set to Boost Promotion after Lifting of Long-Term Prescription Ban

Sales of the proton pump inhibitor (PPI) Nexium (esomeprazole), comarketed by Daiichi Sankyo and AstraZeneca K.K. (AZ), have been sluggish. According to Daiichi Sankyo’s consolidated settlement of accounts for April-June released on July 31, sales of the drug stood at...read more